Compare Jabil Inc (JBL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Sana Biotechnology Inc — how do they compare? Jabil Inc trades at $306.25 (market cap $31.35B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Jabil Inc is far larger — about 37.5× Sana Biotechnology Inc's market cap, and Jabil Inc pays a 0.11% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 23 Days and Sana Biotechnology Inc for 23 Days on average.
| JBL | SANA | |
|---|---|---|
Market Cap | $31.35B | $836.71M |
Volume | 1,337,978 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $385.50 | $5.92 |
52-Week Low | $192.49 | $2.68 |
Typical Hold Time | 23 Days | 23 Days |
Enterprise Value | $33.63B | $749.96M |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $305.83, up 2.12% with strong Q4 2026 earnings beating estimates at $4.40 EPS versus $4.07 expected. Technical indicators show bearish signals with price near resistance at $304, while fundamentals reveal robust revenue growth to $36.0B projected for 2026 and a high ROE of 74.11%. Recent news highlights AI infrastructure demand driving fiscal 2027 growth targets of 24%.
The outlook is positive with analyst consensus price target of $434.75 implying 42% upside, supported by 14 buy ratings and no sells. Risks include high debt levels and market volatility despite strong earnings, but AI-driven expansion and consistent earnings beats present a compelling growth opportunity for investors.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
